NasdaqGS - Delayed Quote • USD
At close: June 7 at 4:00 PM EDT
After hours: June 7 at 5:44 PM EDT
Line
Candle
Baseline
Mountain
Bar
Loading Chart for ZYXI
9/21 12:03 PM
DELL
Date | |
Close | |
Open | |
High | |
Low | |
Volume |
- Previous Close
9.64 - Open
9.58 - Bid 9.55 x 300
- Ask 9.61 x 300
- Day's Range
9.55 - 9.72 - 52 Week Range
6.88 - 13.77 - Volume
68,743 - Avg. Volume
133,130 - Market Cap (intraday)
304.724M - Beta (5Y Monthly) 0.62
- PE Ratio (TTM)
41.70 - EPS (TTM)
0.23 - Earnings Date Jul 25, 2024 - Jul 29, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Jan 5, 2022
- 1y Target Est
19.88
Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.
1,100
Full Time Employees
December 31
Fiscal Year Ends
Healthcare
Sector
Medical Distribution
Industry
More about Zynex, Inc.
Recent News: ZYXI
All SEC Filings
Corporate Changes & Voting Matters
Periodic Financial Reports
Proxy Statements
Tender Offer/Acquisition Reports
Offering Registrations
Performance Overview: ZYXI
Trailing total returns as of 6/7/2024, which may include dividends or other distributions. Benchmark is
YTD Return
ZYXI
11.94%
S&P 500
12.10%
1-Year Return
ZYXI
4.47%
S&P 500
24.82%
3-Year Return
ZYXI
32.19%
S&P 500
26.41%
5-Year Return
ZYXI
26.08%
S&P 500
88.04%
Compare To: ZYXI
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
9.59
-0.52%
Mkt Cap 304.724M
Industry Medical Distribution
68.51
-0.13%
Mkt Cap 8.773B
Industry Medical Distribution
17.36
-1.75%
Mkt Cap 1.328B
Industry Medical Distribution
23.78
-0.29%
Mkt Cap 2.13B
Industry Medical Distribution
235.47
-0.51%
Mkt Cap 46.371B
Industry Medical Distribution
5.25
+0.57%
Mkt Cap 194.795M
Industry Medical Distribution
14.13
0.00%
Mkt Cap 8.837B
Industry Medical Distribution
1.1200
-1.75%
Mkt Cap 95.944M
Industry Medical Distribution
586.90
+0.13%
Mkt Cap 76.289B
Industry Medical Distribution
0.6198
-4.66%
Mkt Cap 10.441M
Industry Medical Distribution
Statistics: ZYXI
Valuation Measures
As of 6/7/2024
Market Cap
304.72M
Enterprise Value
347.30M
Trailing P/E
41.64
Forward P/E
19.19
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.78
Price/Book (mrq)
9.21
Enterprise Value/Revenue
1.84
Enterprise Value/EBITDA
20.44
Financial Highlights
Profitability and Income Statement
Profit Margin
4.33%
Return on Assets (ttm)
5.81%
Return on Equity (ttm)
16.75%
Revenue (ttm)
188.68M
Net Income Avi to Common (ttm)
8.17M
Diluted EPS (ttm)
0.23
Balance Sheet and Cash Flow
Total Cash (mrq)
32.86M
Total Debt/Equity (mrq)
227.90%
Levered Free Cash Flow (ttm)
19.45M
Research Analysis: ZYXI
People Also Watch
GTHX G1 Therapeutics, Inc.
3.0100
+1.35%
KRMD KORU Medical Systems, Inc.
2.2200
-3.06%
SMLR Semler Scientific, Inc.
31.63
+8.58%
PGNY Progyny, Inc.
27.60
-1.18%
PAYS Paysign, Inc.
4.0700
-4.01%
PLMR Palomar Holdings, Inc.
86.86
+0.80%
SLP Simulations Plus, Inc.
46.22
-1.55%
XPEL XPEL, Inc.
39.14
-1.01%
TMDX TransMedics Group, Inc.
137.18
+3.13%
QDEL QuidelOrtho Corporation
41.67
-2.14%
BTAI BioXcel Therapeutics, Inc.
1.4150
-4.39%
NARI Inari Medical, Inc.
48.67
-1.64%
OPRX OptimizeRx Corporation
11.12
-1.51%
SWAV Shockwave Medical, Inc.
334.75
0.00%
INMD InMode Ltd.
18.25
-0.65%
TCMD Tactile Systems Technology, Inc.
12.03
-1.23%